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Abstract
While numerous hypotheses have been proposed to explain the molecular mechanisms underlying
the pathogenesis of neurodegenerative diseases, the theory of oxidative stress has received
considerable support. Although many correlations have been established and encouraging evidence
has been obtained, conclusive proof of causation for the oxidative stress hypothesis is lacking and
potential cures have not emerged. Therefore it is likely that other factors, possibly in coordination
with oxidative stress, contribute to neuron death. Using Parkinson's disease (PD) as the paradigm,
this review explores the hypothesis that oxidative modifications, mitochondrial functional
disruption, and impairment of protein degradation constitute three interrelated molecular
pathways that execute neuron death. These intertwined events are the consequence of
environmental exposure, genetic factors, and endogenous risks and constitute a "Bermuda triangle"
that may be considered the underlying cause of neurodegenerative pathogenesis.
Review
A "Bermuda Triangle" of Insults Induces 
Neurodegeneration
Understanding the molecular basis of neurodegenerative
diseases has proven to be a major challenge, yet is vitally
important because of the prevalence of these chronic con-
ditions in the aging population. While diverse neurode-
generative disorders, which encompass Alzheimer's
disease (AD), Parkinson's disease (PD), Huntington's dis-
ease (HD), and Amyotrophic Lateral Sclerosis (ALS),
involve unique proteins and selectively disparate brain
regions, they share two key features: formation of insolu-
ble protein aggregates and neuron degeneration [1].
Therefore it is reasonable to speculate that a common
causative process underlies the pathogenesis of neurode-
generative disorders. Specifically focusing on PD, this
review proposes that neurodegeneration is due to three
interrelated molecular mechanisms: oxidative modifica-
tions, mitochondrial dysfunction, and impaired protein
degradation.
One possible unifying molecular mechanism that can
induce both the formation of protein inclusions and neu-
ron degeneration is the oxidative reactions derived from
the production of reactive oxygen and nitrogen species. A
substantial increase in oxidized proteins, lipids, and DNA
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has been found in postmortem brain tissue of PD patients
as compared to age-matched disease-free subjects [2].
Although these observations do not demonstrate that oxi-
dative processes are the sole cause of neuronal demise,
they are consistent with data in animal and cellular model
systems (reviewed below) that establish a role for oxida-
tion in neurodegeneration and death.
The four electron reduction of oxygen to water is a funda-
mental biochemical process largely responsible for the
survival of organisms in aerobic environments. Oxidation
and reduction reactions are also important in the central
nervous system for the formation and metabolic process-
ing of catecholamines, for the production of signaling
molecules such as nitric oxide, and for the metabolism of
xenobiotics. The coupling of these enzymatic systems
ensures that electrons are transferred to the desired sub-
strate, avoiding partial reduction of oxygen to reactive spe-
cies. However, inappropriate reduction of oxygen does
occur occasionally, resulting in the production of superox-
ide and hydrogen peroxide.
Mitochondria are considered a key source of reactive spe-
cies. Interruptions or disturbances in the electron trans-
port chain allow electrons to be transferred and reduce
molecular oxygen by one electron to form superoxide, or
by two electrons to form hydrogen peroxide. In addition
to generating ATP, mitochondria also play critical roles in
regulating cellular viability. Therefore, functional com-
promise of this organelle has a large impact on oxidative
homeostasis. To protect against reactive species, a network
of antioxidant enzymes including Cu, Zn superoxide dis-
mutase (SOD) in the cytosol, Mn SOD in the mitochon-
dria, peroxidases, and catalase secure conversion of these
reactive species to water and therefore prevent adverse oxi-
dation of cellular macromolecules.
How then do reactive species induce stress? The answer to
this question is not entirely understood but several sug-
gestions have been advanced. A significant increase in the
rate of reactive species production, potentially coupled
with a decline in the efficiency of the antioxidant net-
works that remove them may permit secondary reactions
with cellular biomolecules (proteins, lipids, DNA/RNA)
that result in undesired oxidations. While neuronal
homeostasis can be disturbed by these oxidative modifica-
tions, protective mechanisms including protein degrada-
tion, lipid turnover, and DNA repair sustain cellular
homeostasis by repairing or removing the oxidized mac-
romolecules. However, compromise of these defense
mechanisms – either by direct oxidative modification or
indirectly by the inability to process oxidatively modified
substrates – may render the cell incapable of efficiently
removing oxidized biomolecules, resulting in their accu-
mulation.
Alteration of protein folding and degradation, due to oxi-
dative stress, mitochondrial dysfunction, or other factors
has been strongly associated with neurodegenerative dis-
eases. Protein aggregation is a hallmark of a diverse array
of these late-onset neurodegenerative disorders, and thus
factors that influence protein folding, processing, and
clearance have been a focus of much research. Two major
pathways are responsible for the degradation of cellular
proteins: the ubiquitin-proteasome system (UPS) [3] and
the autophagy-lysosome pathway [4-6].
The UPS is the principal mechanism of degradation for
short-lived proteins and proteins that are misfolded in the
endoplasmic reticulum [5]. UPS substrates are selectively
targeted for degradation by the 20S or 26S proteasome
complex after the conjugation of a polyubiquitin tag
through a three-step enzymatic cascade [7]. Upon recruit-
ment to the proteasome, the substrates must be unfolded
to pass through the narrow barrel of the proteasome
where they are degraded [5,7]. The consistent observation
that antibodies against ubiquitin label some of the
human and rodent protein inclusions suggests that failure
of the UPS may contribute to neurodegeneration. How-
ever, the effect of UPS inhibition on cell death and protein
aggregation in cellular model systems as well as rodent
models has yielded conflicting results that have not been
entirely resolved [8-13]. These variable results suggest that
other factors, including other protein degradation path-
ways such as autophagy and mitochondrial dysfunction
associated with a decline in ATP levels, may contribute to
cellular viability. This hypothesis remains to be further
explored in cellular and rodent model systems.
The other primary pathway for protein degradation in the
cell is through autophagy. While the ultimate result of
autophagy is always the delivery of proteins or organelles
to the lysosome for degradation, there are three different
routes by which this can be accomplished. Macroau-
tophagy is a non-selective method of bulk degradation
whose activity is upregulated in response to stress. Micro-
autophagy is also a non-selective process, though it is
maintained at a constitutively active state. The final type
of autophagy is chaperone-mediated autophagy (CMA).
Like macroautophagy, CMA is present at low basal levels
in the cell and is upregulated in response to stress. How-
ever, CMA is unique from the other two forms of
autophagy in that it is a selective process [4,14]. While the
UPS, macroautophagy, and CMA have been implicated as
potential contributors to neurodegeneration, their precise
involvement is controversial and unclear.
Macroautophagy was first implicated in neurodegenera-
tion after it was noted that autophagic structures were
present in affected brain regions of patients with neurode-
generative diseases, including PD [15-18]. Initial hypoth-Molecular Neurodegeneration 2009, 4:24 http://www.molecularneurodegeneration.com/content/4/1/24
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eses speculated that these autophagic vacuoles were
evidence of neurons "eating themselves to death" [15].
This was based on previous observations that autophagic
mechanisms can participate in induction of non-apop-
totic cell death cascades [19-25]. However, recent evi-
dence has shown that, particularly within the context of
neurodegeneration, macroautophagy may instead serve as
a protective process by which cells attempt to clear mis-
folded proteins and damaged organelles[4]. Independ-
ently generated data has revealed the neuroprotective role
of macroautophagy through manipulation of either Atg7
or Atg5 – two different proteins essential for autophagy.
Conditionally knocking out either of these genes in the
central nervous system of mice leads to severe neurode-
generation and formation of protein inclusions, accompa-
nied by motor dysfunction and early death [26,27]. In
cells, inhibition of macroautophagy at the stage of
autophagosome formation by 3-methyladenine (3-MA),
at the stage of autophagosome-lysosome fusion by Bafilo-
mycin A1 (BafA1), or at the stage of lysosomal degrada-
tion by deficiency of the enzyme cathepsin D, led to
enhanced aggregation of polygluatmine, polyalanine, and
α-synuclein proteins [28-30]. In contrast, the induction of
autophagy leds to increased clearance and reduced toxic-
ity of pathogenic proteins, decreased aggregate formation
and neurodegeneration, and improved behavioral pheno-
type in fly and mouse models [29-35]. Stimulation of
autophagy has been accomplished either by rapamycin,
which inhibits the negative regulator of autophapgy
mammalian target of rapamycin (mTOR), or by several
mTOR independent compounds including lithium, treha-
lose, and small molecules identified in a screen [29-35].
CMA may also be playing a role in cell vulnerability. In
CMA deficient cells, baseline levels of survival were unaf-
fected, but stressors such as UV light or multiple types of
oxidative stress significantly reduced viability [36]. Addi-
tionally, the proteins implicated in neurodegenerative dis-
ease, APP, Htt, and α-synuclein, all contain a putative
CMA targeting motif, indicating that regulation of this
degradation system may have important effects on patho-
genic protein homeostasis[14].
The UPS, macroautophagy, and CMA are each involved in
the degradation of oxidized proteins. In response to mod-
erate levels of oxidative stress, cells are able to induce a
protective upregulation of all three of these protein degra-
dation pathways, supporting an interplay between protein
oxidation and protein degradation during normal home-
ostasis [4,37-43].
However, more severe oxidative stress impairs the degra-
dation of oxidized proteins [39,40,44]. For the UPS sys-
tem, oxidative modifications that induce crosslinking,
misfolding, and aggregation prevent the proper unfolding
necessary for substrates to be passed through the barrel of
the proteasome for degradation, making these substrates
resistant to degradation as well as potentially inhibiting
the overall activity of the proteasome [45-48]. Addition-
ally, direct oxidative modification of the proteasome sub-
units inhibits 20S and 26S catalytic peptidase activity
[46,49-54]. In a rat model of ischemia/reperfusion, the
lipid peroxidation product 4-hydroxyl-2-noneal (HNE)
impaired the peptidase activity of the proteasome by
direct oxidative modification of the α-like 20S proteas-
ome subunits iota, C3, and an isoform of XAPC7 [53,54].
Additionally, oxidatively modified proteins may impair
the cellular machinery of autophagic degradation [55].
Reactive species can damage the lysosomal membrane
and crosslink membrane proteins, resulting in cytosolic
leakage of lysosomal hydrolases [56-58]. Some oxida-
tively modified aggregated species are resistant to degrada-
tion by proteases and accumulate within lysosomes.
There, the non-degraded proteins become a potential new
source of reactive species, further damaging the lysosomal
membrane [59].
Below we discuss evidence that implicates known envi-
ronmental, genetic, and endogenous factors as contribu-
tors that intitiate oxidative modifications, mitochondrial
dysfunction, and protein aggregation in PD (Figure 1). We
propose that the combined interactions of these three
interrelated molecular pathways – oxidative modifica-
tions, mitochondrial dysfunction, and impaired protein
degradation – constitute a "Bermuda Triangle" that ulti-
mately induces neuron death.
Environmental Toxins
One of the most striking clues into the processes involved
in PD came from the observation of rapid-onset motor
impairments that replicated most of the features of spo-
radic PD in individuals accidentally exposed to 1-Methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [60]. Fur-
ther epidemiological studies have suggested that exposure
to other pesticides and environmental toxins are associ-
ated with PD development. Through their implied ability
to target mitochondria, disrupt dopamine metabolism,
and participate in the formation of oxidants, these toxins
initiate a cascade of deleterious events that can cause the
progressive degeneration observed in disease [61].
In addition to the prototypical example of MPTP, a host
of other compounds that generate oxidative and nitrative
stress (defined as the formation of nitric oxide-dependent
oxidants) have been found to be harmful to neurons.
These agents have been used for the creation of intoxica-
tion models in rodents and non-human primates that
reproduce some of the neuropathological findings and
behavioral symptoms of the human disease. These intox-Molecular Neurodegeneration 2009, 4:24 http://www.molecularneurodegeneration.com/content/4/1/24
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ication models described below are valuable in under-
standing the role of oxidative mechanisms, mitochondrial
dysfunction, and protein aggregation in neuron death and
the selective vulnerability of the nigrostriatal pathway.
Mechanistically, MPP+, the active metabolite of MPTP, is
selectively taken up by dopaminergic neurons where it is
suggested to inhibit complex I of the mitochondrial respi-
ratory chain, inhibit the uptake of dopamine, and partici-
pate in oxidation-reduction biochemistry [62]. MPTP
administration, widely used in non-human primates and
mice, has been shown to replicate many features of PD,
including motor phenotype, degeneration of nigral
dopaminergic neurons, and formation of α-synuclein
A "Bermuda Triangle" of insults leads to neurondeath in PD Figure 1
A "Bermuda Triangle" of insults leads to neurondeath in PD. Known risk factors for the onset of Parkinson's disease 
(PD) include environmental (green), genetic (purple), and endogenous (blue) influences. Contributions from these risk factors 
trigger oxidative modifications, mitochondrial dysfunction, and impaired protein degradation that together form a "Bermuda 
triangle" of interrelated molecular events that underlie neurodegeneration. The interactions between these pathways are sup-
ported by the following (for details and citations, please refer to text): (1) Disturbances in mitochondrial respiration generate 
reactive oxygen species. (2) Overexpression of SOD is protective against mitochondrial toxins. (3) NOS deficiency or inhibi-
tion attenuates MPTP, paraquat, and rotenone toxicity. (4) Inhibition of degradation systems leads to increased sensitivity to 
oxidative stressors. (5) Impaired degradation leads to an accumulation of substrates, increasing the probability for oxidative 
modifications. (6) Excessive production of reactive oxygen and nitrogen species modifies proteins, leading to inactivation, 
crosslinking, and aggregation. (7) α-Synuclein modified by oxidized dopamine impedes CMA. (8) Oxidative modifications mod-
ify the lysosomal membrane and crosslink membrane proteins. (9) UPS and CMA are not able to unfold and remove oxidatively 
proteins. (10) Oxidative modification of proteasome subunits inhibits UPS function. (11) Macroautophagy is the principle mech-
anism for the degradation of damaged mitochondria. (12) Proteasome inhibition increases mitochondrial reactive species gen-
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positive filamentous proteinaceous inclusions resembling
Lewy Bodies [63-66].
The concept that oxidative processes are playing a major
role in the demise of the catecholaminergic neurons is
reinforced by data documenting that mice over-expressing
the antioxidant protein cytosolic SOD1 [67] are protected
against MPTP toxicity. Additionally, the contribution of
reactive nitrogen species to MPTP-induced neuron injury
is revealed by studies in nitric oxide synthase (NOS) defi-
cient animals. MPTP toxicity is attenuated in either iNOS
or nNOS deficient mice [68,69] or mice that are treated
with nNOS inhibitors [70,71] suggesting that nitric oxide-
derived oxidants are participants in the oxidative and
nitrative processes that lead to MPTP-induced neurode-
generation.
The herbicide paraquat, a biologically redox active mole-
cule, is a toxin that has deleterious effects on neurons.
Paraquat is used in mouse models of neurodegeneration
and leads to reduced motor activity, cell death selectively
within the dopaminergic neurons of the substantia nigra,
and degeneration of the striatal fibers in a dose-dependent
way [72,73]. Additionally, systemic administration of
paraquat results in upregulation of α-synuclein expression
and the formation of aggregates [74], similar to changes
that have been reported following administration of
MPTP [75]. Overexpression of SOD in cells or mice has
been shown to protect against paraquat toxicity, support-
ing the role of oxidative stress in neuron death [76-79].
Delivery of molecules with SOD/catalase and antioxidant
scavenging capacity such as MnTBAP or EUK-189 were
shown to have a similar effect [80-82], although recent
studies have indicated that this protection against
paraquat may be due to antioxidant-independent mecha-
nisms of MnTBAP including prevention of mitochondrial
Ca2+ accumulation [83,84].
Rotenone is an insecticide that selectively inhibits mito-
chondrial complex I. It has been used in rat models to pro-
duce a Parkinson-like phenotype including selective
degeneration of the dopaminergic neurons of the nigros-
triatal region, motor impairment, and fibrillar inclusions
[85]. Unlike MPTP, rotenone is highly lipophilic and con-
sequently can enter any cell type [86]. Therefore, rotenone
could potentially inhibit mitochondrial complex I
throughout the brain. However, rats chronically infused
with rotenone develop selective nigral degeneration and
α-synuclein positive, Lewy body-like inclusions indicating
that dopaminergic cells are somehow exquisitely sensitive
to mitochondrial impairment [85]. The molecular details
underlying this inherent dopaminergic neuron vulnera-
bility still require further investigation, and will be dis-
cussed below.
Finally, 6-hydroxydopamine (6-OHDA), a prototypical
oxidative stress toxin used in animal models for over 30
years, mimics PD by causing degeneration of the
dopaminergic neurons [87,88]. 6-OHDA is structurally
similar to dopamine and norepinephrine and thus can
accumulate in catecholaminergic cells. In the presence of
oxygen and transition metals it oxidizes into para-qui-
none and hydrogen peroxide, with superoxide (O2
.-) and
semi-quinone radicals as intermediate species of the reac-
tion [89]. The generation of reactive species and strong
electrophiles attacking nucleophilic groups and inactivat-
ing macromolecules have been shown to contribute to
neurodegeneration [87,88]. Injection of 6-OHDA in the
substantia nigra of rats leads to rapid death of dopamin-
ergic neurons, while injection in the stiatum induces a ret-
rograde degeneration of the neurons in the substantia
nigra [90-92].
Genetic Links
While the majority of PD cases are sporadic, rare instances
of genetic heritability have helped to provide further
insight into the mechanisms contributing to disease. Cur-
rently, thirteen genetic loci, denoted PARK1–13, have
been associated with PD [93]. From these loci, six genes
have been established as a causative factor of familial PD:
α-synuclein (PARK1/4), parkin (PARK2), PINK1
(PARK6), DJ-1 (PARK7), LRRK2 (PARK8), and ATP13A2
(PARK9) [93-95]. ATP13A2 is a lysosomal P-type ATPase
that has been associated with a recessive juvenile form of
PD [96]. A recent studies highlighted a genetic interaction
between ATP13A2 and α-synuclein and showed that
ATP13A2 is able to modulate α-synuclein toxicity [97].
However, while ATP13A2's lysosomal location reinforces
the importance of autophagic degradation, this review
will focus on the other five PD genes that have been most
extensively investigated. Each of these five genes (DJ-1,
PINK1, Parkin, LRRK2, and α-synculein) has yielded data
supporting critical associations with mitochondrial and
oxidative processes and protein degradation.
DJ-1
Mutations and deletions in the gene encoding DJ-1 have
been linked to recessive familial PD. DJ-1 is a mitochon-
drial-associated protein which has been suggested to func-
tion as an antioxidant with peroxidredoxin-like activity
[98-100]. Mass spectrometry and other methodologies
have indentified Cys106 in DJ-1 as the critical amino acid
for DJ-1 mediated protection against oxidative stress as
well as for the relocation of DJ-1 to the mitochondria dur-
ing oxidative stress [101]. Irreversible oxidation of this
residue renders the protein incapable of protecting cells
from oxidant insults [102].
Support for a role of DJ-1 as a protective antioxidant pro-
tein is derived from experiments demonstrating thatMolecular Neurodegeneration 2009, 4:24 http://www.molecularneurodegeneration.com/content/4/1/24
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knockout/knockdown of DJ-1 or expression of DJ-1 with
a pathogenic mutation in cells leads to an increased sensi-
tivity to oxidative stress [99,103]. Similarly, increased sen-
sitivity to neurotoxins that generate oxidative stress such
as MPTP, rotenone, and paraquat has been documented
in DJ-1 deficient drosophila and mice [104-108]. Corre-
spondingly, over-expression of DJ-1 protects against oxi-
dative insults. In dopaminergic cell lines, overexpression
of wild type, but not mutant, DJ-1 was able to protect cells
from hydrogen peroxide and 6-OHDA challenges, leading
to reduced levels of reactive species, protein oxidation,
and cell death [109,110]. In animal models, overexpres-
sion of wild type but not mutant DJ-1 was protective
against dopaminergic neural degeneration in mice
exposed to MPTP or rats exposed to 6-OHDA
[108,110,111].
PINK1
PTEN-induced kinase 1(PINK1) is a mitochondrial associ-
ated protein whose loss of function mutations lead to a
recessive form of hereditary early onset PD [112]. PINK1
is a putative serine/threonine kinase with an N-terminal
mitochondrial targeting sequence [113]. Both endog-
enous and recombinant PINK1 are localized to the mito-
chondria in cell culture and a drosophila model [112-
114]. Functionally, it is postulated that PINK1 phosphor-
ylates mitochondrial proteins in response to cellular stress
and thus protects against mitochondrial dysfunction
[112,115]. Additional roles for PINK1 in regulating mito-
chondrial fusion and fission as well as modulating prote-
olytic activity through interaction with the serine protease
HtrA2 have also been proposed [116-119]. Within the
context of disease, lymphoblasts of patients with muta-
tions in PINK1 show increased lipid peroxidation and
defects in mitochondrial complex I activity [120,121].
Additionally, abnormal mitochondrial morphology was
evident in primary cells derived from patients with two
different mutations in PINK1 [120].
PINK1 has been shown to influence cell viability. Knock-
down of PINK1 in SH-SY5Y, HeLa, and mouse primary
neurons, caused abnormal mitochondrial morphology,
compromised mitochondrial function, increased markers
of oxidative stress, and ultimately decreased cell viability
[120,122]. Additionally, those cells were more vulnerable
to challenges by rotenone and the active metabolite of
MPTP, MPP+ [120,123,124]. Conversely, overexpression
of PINK1 in cell models protected against cell death
induced by mitochondrial permeability transition pore
opening, oxidative stress, and proteasome inhibitors. Pro-
tection of cellular viability was related to the ability of
PINK1 to prevent loss of mitochondrial membrane poten-
tial, to suppress cytochrome c release from mitochondria,
and suppress activation of caspase-3 [112,115,125,126].
Expression of PINK1 with pathogenic mutations, expres-
sion of a truncated form of PINK1, or expression of PINK1
lacking the kinase domain eliminated this protective
effect [112,115,125,126].
Similar to the cell models, mitochondrial abnormalities
and increased sensitivity to stressors have also been docu-
mented in PINK1 deficient drosophila [127-130]. This
phenotype was able to be rescued by expression of wild
type but not mutant PINK1 as well as by expression or
administration of SOD-1, further supporting the view that
the protective role of PINK1 is related to oxidative proc-
esses [128,130].
Interestingly, PINK1 knockout mice do not display gener-
alized mitochondrial defects [131]. However, impaired
mitochondrial respiration does occur specifically within
the nigrostriatal dopaminergic circuit, and mitochondria
isolated from the knockout mice display increased sensi-
tivity to hydrogen peroxide [132]. PINK1 knockout mice
also have impaired dopamine release and impaired syn-
aptic plasticity, suggesting a specific role in dopaminergic
neuron function [131]. This has important implications
for the specificity with which dopaminergic neurons are
affected in PD.
Parkin
Identification of loss of function mutations in the gene
encoding the ubiquitin ligase parkin in autosomal reces-
sive PD indicates that dysfunction of the ubiquitin protea-
some system is a contributing factor in the pathogenesis
of PD [133-135]. Additionally, recent evidence implicates
parkin in mitochondrial function and oxidative processes.
Parkin is localized to the mitochondria of proliferating
cells and influences mitochondrial biogenesis [136].
Attempts to examine the effect of parkin modifications on
other proteins have included two dimensional gel electro-
phoresis combined with proteomic analysis in parkin
knockout mice, as well a genetic screen for parkin modifi-
ers and the use of cDNA microarrays to characterize tran-
scriptional alterations in parkin deficient drosophila
[137-139]. These studies report that parkin modulates
expression of proteins involved in the regulation of energy
metabolism, such as subunits of pyruvate dehydrogenase,
mitochondrial complexes I and IV, and ATP synthase, as
well as in proteins involved protection against oxidative
stress, such as peroxiredoxin 1, 2, and 6, Hsp70 related
proteins, carbonyl reductase, and thioredoxin reductase
[137,138]. Drosophila models deficient in parkin or
expressing parkin with a pathogenic mutation exhibit
mitochondrial dysfunction and alterations in oxidative
response components [139,140]. Additionally, parkin
deficient drosophila have increased sensitivity to paraquat
[141]. In parkin knockout mice, impaired mitochondrial
function and decreased antioxidant capacity is accompa-Molecular Neurodegeneration 2009, 4:24 http://www.molecularneurodegeneration.com/content/4/1/24
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nied by nigrostriatal defects, synaptic dysfunction, and
dopaminergic behavioral deficits [138,142].
Parkin overexpression in cultured cells helped prevent
mitochondrial swelling, cytochrome c release, caspase 3
activation, increased reactive species levels, and cell death
[143,144]. In a murine model, viral overexpression of par-
kin was able to inhibit dopaminergic neural loss in mice
exposed to MPTP [111]. As an E3 Ubiquitin ligase, parkin
levels are upregulated in response to unfolded protein
reponse stress induced by the application of the N-glyco-
sylation inhibitor tunicamycin or the reducing agent 2-
mercaptoethanol [145]. Parkin overexpression corre-
spondingly is able to rescue cells from the unfolded pro-
tein response (UPR) induced by various stressors [145].
Additionally, parkin overexpression has been shown to
protect cells against proteasomal dysfunction and death
induced by mutant α-synuclein [146]
Oxidative modifications may also impact parkin itself. S-
nitrosylation, a nitric oxide-derived post-translational
modification, of parkin occurs in vitro, in a mouse model
of PD, and in the brains of PD patients [147]. S-nitrosyla-
tion decreases parkin's ubiquitin E3 ligase activity and its
protective function in cells expressing α-synuclein and
synphilin-1 that were exposed to a proteasome inhibitor
[147,148]. Such consequences provide a mechanism by
which parkin's function may be disrupted and thus con-
tribute to disease progression in sporadic PD. S-nitrosyla-
tion has also been shown to affect the activity of other
proteins relevant to neurodegeneration, including pro-
tein-disulfide isomerase (PDI), an ER chaperone [149]. S-
nitrosylation inhibits PDI's enzymatic activity, preventing
it from promoting the proper folding of proteins during
times of cellular stress and preventing PDI's protective
effect [149].
Recent studies have provided further support for the role
of parkin in oxidative processes by establishing that par-
kin functions downstream of PINK1 within the same
pathway. Drosophila mutants that are deficient in either
parkin or PINK1 exhibit similar phenotypes. Transgenic
expression of parkin is able to rescue the phenotype of
PINK1 deficient flies, although the reverse is not true
[127-129]. This downstream relationship is supported by
the fact that in PINK1 deficient flies, the level of parkin
protein is significantly reduced [128]. Additionally, it has
been shown that DJ-1 with a pathogenic mutation is able
to associate with parkin, and this association is promoted
by oxidative stress [150].
Leucine-rich repeat kinase 2
Recently, leucine-rich repeat kinase 2 (LRRK2) has been
recognized as a cause of an autosomal dominant late-
onset form of familial PD. LRRK2 expression in the brain
largely correlates to the nigrostriatal dopaminergic sys-
tem, although diffuse expression throughout the brain has
also been noted, including expression in the cerebral cor-
tex, hippocampus, and cerebellum [151-154]. Within the
cell, LRRK2 associates largely with membrane bound
structures, including the mitochondria, lysosomes,
plasma membrane, synaptic vesicles, golgi apparatus, and
endoplasmic reticulum and is likely associated with lipid
rafts in these membranes [154-156]. LRRK2 contains
putative GTPase, protein kinase, WD40 repeat, and leu-
cine-rich repeat (LRR) domains, but the endogenous func-
tion of the protein is still being investigated [157].
In support of the role of mutated LRRK2 in neurodegener-
ation, expression of LRRK2 with pathogenic mutations in
SH-SY5Y cells and primary neurons reduced cell viability
[155,158-160]. LRRK2 also affects the ability of the cell to
handle oxidative stress. Overexpression of mutant LRRK2
failed to rescue cultured cells from hydrogen peroxide
exposure, while expression of wild type LRRK2 success-
fully attenuated this stress [161]. Additionally, drosophila
expressing mutant LRRK2 were significantly more sensi-
tive to paraquat and hydrogen peroxide than flies express-
ing wild type LRRK2 or deficient in LRRK2 [162]. The
magnitude of oxidative damage was lowest in drosophila
deficient in LRRK2, while flies expressing the mutant
LRRK2 had the highest levels [162]. While these observa-
tions support the dominant-negative effect of LRRK2
mutations, it is unclear why wild type LRRK2 is more det-
rimental than a deficiency of LRRK2. Further studies need
to be conducted to fully understand both the normal and
pathogenic function of this protein.
α-Synuclein
In addition to the discovery that three different autosomal
dominant missense mutations in the gene encoding α-
synuclein cause early onset, familial PD, wild type α-synu-
clein has also been identified as one of the primary com-
ponents of Lewy bodies in sporadic cases [163-167]. α-
Synuclein is a soluble, relatively unstructured protein,
expressed throughout the central nervous system whose
function relates to synaptic vesicular regulation and to
chaperone-like activity [168-170]. A hydrophobic region
spanning residues 71–82, as well as factors that have not
been fully understood, contribute to the orderly assembly
of α-synuclein into amyloid fibers that ultimately consti-
tute in part the Lewy bodies and other inclusions [171-
173].  α-Synuclein appears to both contribute to mito-
chondrial dysfunction, oxidative stress, and impaired pro-
tein degradation, as well as itself be a target for oxidative
modifications that may affect aggregation and neurotoxic-
ity.
In a cell model, overexpression of α-synuclein led to mito-
chondrial dysfunction and increased levels of reactive spe-Molecular Neurodegeneration 2009, 4:24 http://www.molecularneurodegeneration.com/content/4/1/24
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cies [174]. A similar effect was reported in transgenic mice
expressing α-synuclein with the A53T pathogenic muta-
tion. These mice developed mitochondrial degeneration
and cell death [175]. α-Synuclein additionally appears to
sensitize mice to mitochondrial toxins. Transgenic mice
expressing mutant α-synuclein had increased neural
degeneration, mitochondrial abnormalities, α-synuclein
aggregation, and levels of oxidative and nitrative modifi-
cations after exposure to challenges including MPTP,
paraquat and maneb [176-179]. Importantly, mice that
lack α-synuclein are protected against MPTP toxicity [180-
182]. Recent evidence has also shown that α-synuclein
accumulates within mitochondria due to an N-terminal
targeting sequence, leading to impaired mitochondrial
complex I activity and increased production of reactive
species [183]. Significantly more α-synuclein was accu-
mulated in mitochondria isolated from the substantia
nigra and striatum of patients with sporadic PD than from
controls [183].
α-Synuclein may also play a role in disease through its
effects on protein degradation. It has been suggested that
α-synuclein may initiate UPS inhibition, as it has been
shown to disrupt the proteasome in vitro, an effect that is
enhanced by the pathogenic α-synuclein mutations
[146,184-186]. The mechanisms underlying this inhibi-
tion are not fully understood, though possibilities include
binding of α-synuclein to a subunit of the proteasome,
blockage of the proteasome by aggregated proteins, or
potentially an unknown downstream mechanism. Addi-
tionally, α-synuclein may play a role in autophagy. In vitro
studies have shown α-synuclein is preferentially degraded
by CMA [187]. However pathogenic mutations of synu-
clein or modification by oxidized dopamine cause α-
synuclein to bind strongly to the lysosomal CMA receptor.
This blocks the uptake and degradation of α-synuclein
and other CMA substrates [55,187]. Downstream effects
of this disruption may explain how α-synuclein muta-
tions are able to induce cell death – α-synuclein induced
impaired CMA degradation of myocyte enhancer factor
2D (MEF2D), a transcription factor required for neuronal
survival, resulting in the cytosolic accumulation of
MEF2D that bound poorly to DNA, causing an overall
decrease in MEF2D function [188].
While α-synuclein can modulate mitochondrial function,
oxidative challenges, and protein degradation machinery,
oxidation and nitration also appear to modify α-synuclein
directly and consequently affect its aggregation. α-Synu-
clein nitrated on tyrosine residues has been identified in
the detergent-insoluble fraction of the brains of PD
patients, suggesting that this modification may induce the
aggregation of this protein or that aggregated forms of the
protein are selectively modified by nitrating oxidants
[189]. In cell, mouse, and non-human primate models,
treatment with MPTP has been shown to increase oxida-
tive modifications and aggregation of α-synuclein
[64,75,190]. Treatment of cells or rats with rotenone and
mice with paraquat similarly increased α-synuclein aggre-
gation and inclusion formation and cellular dysfunction
[74,85,191].
Collectively, these findings led to biochemical examina-
tion of the effect of oxidative or nitrative modification on
α-synuclein. Fibrillar α-syncuclein aggregates with a peri-
nuclear localization were formed in cells expressing α-
syncuclein upon kinetically controlled exposure to nitric
oxide and superoxide [192]. Studies with purified protein
revealed that tyrosine nitration effects the ability of α-
synuclein to bind to lipid vesicles and slows the rate of
degradation by the 20S proteasome and calpain-I [193].
Nitration of α-synuclein monomers and dimers is able to
accelerate the rate of fibril formation through the recruit-
ment of non-nitrated α-synuclein, but nitration of oli-
gomers inhibits fibril formation [193-195]. In addition to
nitration, exposure of α-synuclein to nitrating oxidants
also results in the formation of highly stable o, o'-dityro-
sine cross linked dimers and oligomers [196]. o, o'-Dityro-
sine cross linking was found to stabilize pre-formed
fibrils, which significantly accelerate the formation of
fibrilar aggregates. Site-directed mutation of the four tyro-
sine residues in α-synuclein discerned that the tyrosine
residues are essential for crosslinking and stabilization in
response to nitrative insults. [196]. However, oxidative
modifications also are able to affect α-synuclein and
invoke crosslinking and stable fibril formation independ-
ent of tyrosine residues [197]. The C-terminal of α-synu-
clein has been found to be critical for oligomerization of
α-synuclein into detergent insoluble species in response
to oxidation by copper and hydrogen peroxide [198].
Due to the regional specificity of pathology in PD
patients, the effect of dopamine on α-synuclein has also
been investigated. During a chemical compound library
screen for molecules that would inhibit formation of α-
synuclein fibrils, Lansbury and coworkers discovered that
the neurotransmitter dopamine inhibits the formation of
α-synuclein fibrils [199]. The interaction of dopamine
with α-synuclein appeared to arrest the process of fibril
formation at a stage of oligomeric species [199]. We have
extended these observations to indicate that dopamine
oxidation is essential for this kinetic arrest of α-synuclein
oligomers [200]. Since dopamine oxidation generates
reactive species and strong electrophiles, mutational anal-
ysis of putative amino acid targets in α-synuclein that
could be modified by this oxidation was explored [200].
Examination of sites such as the three methionine resi-
dues and histidine 50 revealed that covalent modification
of these amino acids was not responsible for the effects of
oxidized dopamine [200]. The data indicated that theMolecular Neurodegeneration 2009, 4:24 http://www.molecularneurodegeneration.com/content/4/1/24
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interaction of oxidized dopamine with α-synuclein is
directed, not towards a single amino acid, but rather five
amino acid residues: tyrosine-glutamate-methionine-pro-
line-serine (YEMPS) in position 125–129 in the C-termi-
nus of the protein [200,201]. Recent studies have
confirmed these findings and also indicated that the gluta-
mate 83 residue also participates in stabilizing the interac-
tion of oxidized dopamine with the YEMPS region [202].
The in vitro data has been confirmed in cellular model
systems that express A53T α-synuclein or A53T α-synu-
clein with all 5 amino acids 125–129 mutated, establish-
ing the importance of this C terminal region in the
stabilization of α-synuclein oligomers in the presence of
oxidized dopamine [201,203]. The decrease in catecho-
lamine levels that has been described as an early even in
PD pathogenesis [204] may then allow the formation of
insoluble  α-synuclein aggregates later in disease [203].
Additionally,  α-synuclein modified by oxidized
dopamine may have deleterious effects on cellular func-
tion, indicating that aggregation may not be a necessary
prerequisite for cell death. α-Synuclein modified by oxi-
dized dopamine has been shown to block CMA by bind-
ing strongly to the L2A receptor and blocking the uptake
of itself and other substrates [55]. Oligomeric α-synuclein
was shown to bind to the lysosomal membrane but was
unable to be unfolded or taken up into the lysosomes
[55]. Furthermore, α-synuclein modified by oxidized
dopamine was able to decrease neuronal viability to a
degree similar to the effect of L2A RNAi [55]. Therefore α-
synuclein may serve as both a modulator and a target of
oxidative and nitrative modifications.
Endogenous Factors
In addition to evidence from genetic and environmental
risks, the two endogenous factors of aging and dopamine
oxidation have implicated oxidative modifications, mito-
chondrial dysfunction, and impaired protein degradation
in PD.
Aging
In PD, the most significant risk factor for developing dis-
ease is age. The accumulation of proteins altered by oxida-
tive modifications has been shown to increase with age,
which correlates with the late-onset of neurodegenerative
pathology [205,206]. Examination of cultured human
fibroblasts, human brain tissue, as well as tissues from
other organisms have shown that in elderly individuals,
approximately one third of proteins have been oxidatively
modified [206-208]. This increase is not linear but instead
occurs as an initial gradual rise that magnifies several fold
in late age [6,206-208]. Oxidative modifications most
likely accumulate with age due to a combination of
increased production of reactive species, decreased anti-
oxidant function, and impaired ability to repair or remove
the modified proteins.
Dysfunctional clearance has been largely supported by
findings that the activities of the UPS, macroautophagy
and CMA decline with age, consequently diminishing the
ability of the cell to clear modified proteins or protect
itself from damaging free radicals [47,209-216]. Due to
impaired degradation, proteins with oxidative modifica-
tions accumulate in the cell, increasing their propensity
for aggregation [47,216]. Additionally, once the activity of
these degradation pathways is diminished, a feed-forward
effect on oxidative damage may result. Sullivan et al.
found that proteasomal inhibition increased mitochon-
drial reactive species generation and decreased mitochon-
drial complex I and II activity [217]. Therefore, inhibition
of the proteasome and autophagy pathways may be fur-
ther contributing to oxidative damage.
Dopamine Oxidation
The characteristic topology of cell loss that is revealed
from neuropathological studies of PD brains, with the rel-
atively selective vulnerability of the ventrolateral and cau-
dal regions of the substantia nigra pars compacta, can
provide useful clues on the etiology of the disease. In par-
ticular, it has been postulated that the oxidative environ-
ment of dopaminergic neurons might be a key
component in the pathogenesis of PD. Typically,
dopamine is rapidly sequestered within vesicles by the
vesicular monoamine transporter, where the acidic pH
significantly delays the oxidation of dopamine. However,
an oxidative environment can be created if dopamine
remains in the cytosol, where it can oxidize at physiologi-
cal pH to generate reactive ortho-quinones, aminoc-
hromes, as well as superoxide and hydrogen peroxide
[218,219]. Excessive cytosolic oxidation of catechols has
been shown to be neurotoxic in cell culture and rodent
models [220-222]. However, it is unclear whether intrac-
ellular oxidation of dopamine is able to significantly con-
tribute to the neuron injury.
The gradual accumulation of oxidized dopamine that
occurs in normal aging does not appear sufficient to
induce neuronal death. However, a consequence of the
accrual of oxidized dopamine is the formation of neu-
romelanin. Neuromelanin, the substance that gives the
dopaminergic neurons of the substantia nigra their char-
acteristic dark appearance, is a polymer of oxidized and
subsequently heterocyclized dopamine. It has been pro-
posed that the polymer is sequestered within the neurons
to form a new cellular organelle of unknown function
[223]. In that capacity it has been hypothesized that the
neuromelanin polymer might be neuroprotective by fur-
ther chelating toxins and transition metals such as iron
and manganese [223-226]. Since divalent redox capable
metals such as iron participate in catalytic reactions with
hydrogen peroxide to generate potent oxidizing species,
such a role would be crucial to protecting neurons. EffortsMolecular Neurodegeneration 2009, 4:24 http://www.molecularneurodegeneration.com/content/4/1/24
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to limit the availability of iron have been found to protect
neurons from injury and death [227-230].
Alternatively, other studies have revealed a correlation in
PD brains between cell loss and the presence of neuromel-
anin, which suggests that the neuromelanin-pigmented
subpopulation of dopaminergic neurons are more vulner-
able in disease [231]. Another interesting but unexplored
observation is the co-localization of the characteristic pro-
tein inclusions (Lewy bodies) in close proximity to neu-
romelanin in human post mortem PD brains [232,233].
It is possible that the synthesis of neuromelanin, which
requires the oxidation of dopamine and the formation of
oxidants and electrophiles, promotes the formation of
protein aggregates by oxidizing proteins, providing a scaf-
fold for protein filament assembly, or both. In support of
its role as a scaffold for aggregation, the melanosome has
been shown to be crucial for the assembly of the non-
pathogenic natively amyloidogenic protein Pmel17 [234].
Additionally, the melanosome precursor itself assembles
into amyloid-like fibrils that may promote the association
and assembly of other amyloidogenic proteins [235].
Aggregation may also been promoted by the raft like lipid
component of neuromelanin, as hydrophobic interac-
tions would bring macromolecules in close proximity
[235,236]. Another interesting observation is that the
presence of neuromelanin in dopaminergic neurons is
unique to primates, which may explain inconsistencies in
the attempts to recapitulate disease in rodent models
[237-240].
Conclusion
Examining the "Bermuda triangle" in which dopamine
neurons are lost, oxidative modifications, mitochondrial
dysfunction, and impaired protein degradation appear to
be three interrelated molecular pathways responsible for
the pathogenesis of both sporadic and familial PD (Figure
1). Evidence from environmental, genetic, and endog-
enous factors highlights the interplay of these three mech-
anisms as the common detrimental denominators
inducing neuronal death. Not only do these three proc-
esses have clear impacts on cellular viability, but their par-
ticipation explains other characteristic features of disease,
such as the presence of oxidized proteins, inclusions,
increased prevalence with late age, and dopaminergic
regional selectivity. Together, through their effects on cel-
lular homeostasis and their interactions with one another,
oxidative stress, mitochondrial dysfunction, and impaired
protein degradation provide the final impetus with which
insult to neurons is transformed into neurodegenerative
disease.
Currently, treatment for PD is focused merely on alleviat-
ing symptoms. As research progresses towards a better
understanding of the molecular mechanisms underlying
disease, hopefully a more effective therapy can ultimately
be designed. Current trials to deliver compounds that can
restore mitochondrial function and reduce oxidative bur-
den will be informative and not only improve therapeutic
treatment of PD but also provide vital results to guide
future studies investigating the molecular mechanisms of
neurodegeneration.
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